Covid-19 vaccines

View All

MedTech News for NeuroLogica, Medtronic, and Pfizer
Biosense Webster’s HELIOSTAR Radiofrequency Balloon Ablation Catheter; Philips’s ClarifEye Augmented Reality Surgical Navigation Solution; NeuroLogica’s Elite Mobile Computed Tomography Devices; Medtronic’s Natural Conduction System for Heart; Pfizer & BioNTech’s Omicron BA.4/BA.5-Adapted Bivalent Booster Trial; Castle Biosciences’s TissueCypher® Barrett’s Esophagus Test

HELIOSTAR™ Radiofrequency Balloon Ablation Catheter Launched by Biosense Webster in Europe On October 12, 2022, Biosense Webster, a part of Johnson & Johnson Medical technology, announced the launch of HELIOSTAR™ Balloon Ablation Catheter, the first radiofrequency balloon ablation catheter in E...

Find More

vaccines-market-outlook
Comprehensive Assessment of the Leading Companies in the Vaccines Market

Millions of lives are saved annually all because of vaccination, which is a success story in global health and development. More than 20 life-threatening diseases can now be prevented with vaccines, allowing individuals of all ages to live longer, healthier lives. Vaccines prevent 3.5–5 million deaths yearly from d...

Find More

pharma-news-for-pfizer-lilly-innovent-bayer-gsk-daewon
Pfizer & Lilly’s JAK Inhibitors Drug; FDA Approves Lilly’s Bebtelovimab; GSK’s Benlysta; Daewon’s Non-steroidal Anti-inflammatory Drug; Lilly & Innovent’s Lung Cancer Drug; Bayer’s Asundexian

Pfizer and Lilly's JAK Inhibitors Safety Concerns Prompt Europe to Investigate the Drug Class The risk of heart problems associated with the use of JAK inhibitors has called the entire drug class into question. In September, the FDA announced that it would require safety warnings for drugs such as Pfizer's Xelja...

Find More

pharma-news-for-accutar-bio-thera-nykode-heat-biologics-elusys
Accutar’s Phase I clinical trial for AC0176; Bio-Thera’s cancer drug, BAT6005; Nykode’s Covid-19 vaccine trial; Heat Biologics acquires Elusys

FDA approves IND application of Accutar for a prostate cancer treatment trial The US Food and Drug Administration (FDA) has granted Accutar Biotechnology’s Investigational New Drug (IND) application for Phase I clinical trial of AC0176 for treating metastatic castration-resistant prostate cancer (mCRPC). An i...

Find More

monoclonal-antibody-therapy
What are Monoclonal Antibodies and How Can They Treat COVID-19?

An antibody is a protein produced by the immune system in response to an infection in the body. Whereas, a monoclonal antibody is a molecule produced in a laboratory specifically designed to enhance the body’s natural immune system response against an invader, such as cancer or an infection. Monoclonal antibodies h...

Find More

pharma-news-for-ge-optellum-therapixel-ocugen-blueprint
GE Healthcare-Optellum’s collaboration; Ocugen’s Covid-19 vaccine trial; Blueprint to acquire Lengo Therapeutics; Therapixel’s Mammoscreen

GE Healthcare, Optellum collaborate for AI-based lung cancer diagnosis GE Healthcare has collaborated with Optellum to progress precision diagnosis and lung cancer treatment with artificial intelligence. The partnership is zeroed in on helping healthcare providers to evaluate the malignancy of a lung nodule a...

Find More

Latest-medtech-news-updates-for-abbott-wren-smithnephew-hyalex
MedTech Wrap Up

Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius® High-Frequency Nerve Block System On June 29, 2021, the US Food and Drug Administration (FDA) granted Neuros Medical, Inc. Breakthrough Device Designation for the use of their unique Altius High-Frequency Nerve Block device in...

Find More

pharma-happenings-for-jnj-bayer-novo-prothena
Bayer’s CKD Drug; Enochian’s RNA Hijack for HBV; Novo Nordisk’s to get Prothena’s ATTR Amyloidosis Business; J&J’s COVID-19 Vaccine Struggle

Bayer Scores FDA-Approval for its CKD Drug Finerenone Following a priority review, the USFDA finally gave its thumbs-up to Bayer AG’s Kerendia (finerenone) for chronic kidney disease (CKD) associated with type 2 diabetes (T2D) based on the results from the Phase III FIDELIO-DKD study. Finerenone is the first ...

Find More

Coronavirus-covid-19-vaccine-landscape
Charting out the COVID-19 Vaccine Landscape

The uncontrolled outbreaks of Covid-19 have brought unprecedented challenges to the world community. It has created an imbalance in mental, social, and economic well-being. Apart from this, it has changed the overall way of living and has created fear and anxiety among people. Countries are experiencing peaks, one ...

Find More

recent-pharma-biotech-news-updates-for-sanofi-gsk-apellis-innocare-landos
InnoCare’s Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab

InnoCare Receives Go-ahead for Clinical Trial of TYK2 Inhibitor ICP-332 in China InnoCare, a biopharma firm developing novel therapies for the treatment of cancer and autoimmune diseases, today announced the approval of Phase I clinical trial of its novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, by the China...

Find More